Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

Key Points

• Ventyx Biosciences (VTYX) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.45) per share.
• The company's shares have decreased by 1.9% and are currently trading at $2.53, having a market cap of $180.03 million.
• Institutional investors hold 97.88% of Ventyx Biosciences' stock, with notable increases in holdings from firms like Acadian Asset Management and AQR Capital Management.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.07. On average, analysts expect Ventyx Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Stock Up 19.1%

Ventyx Biosciences stock traded up $0.45 during mid-day trading on Friday, hitting $2.81. 1,892,363 shares of the stock were exchanged, compared to its average volume of 952,532. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $3.39. The firm's fifty day simple moving average is $2.55 and its two-hundred day simple moving average is $1.82. The stock has a market capitalization of $199.96 million, a price-to-earnings ratio of -1.67 and a beta of 0.97.

Institutional Trading of Ventyx Biosciences

Several large investors have recently modified their holdings of VTYX. AQR Capital Management LLC grew its position in shares of Ventyx Biosciences by 925.6% during the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company's stock worth $1,012,000 after buying an additional 794,401 shares during the period. Acadian Asset Management LLC grew its position in shares of Ventyx Biosciences by 443.8% during the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company's stock worth $614,000 after buying an additional 438,286 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Ventyx Biosciences during the 1st quarter worth approximately $56,000. Institutional investors and hedge funds own 97.88% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.